The data and analysis from a multicenter open-label study showed elacytarabine a significantly superior survival benefit compared to published clinical data for 594 late-stage AML patients have investigators choice of treatment. The results confirm the positive results of the study in June 2009 announced.
The poster entitled A Phase II Multicenter Study with Elacytarabine as Second Salvage Therapy in Patients with AML by Susan by Susan O’Brien, MD of the University of Texas MD Anderson Cancer Center, Houston, TX, in collaboration with researchers at other leading cancer centers and Clavis Pharma. This is the first time, clinical results of this study for all 61 patients were presented at a major cancer conference.Women tend to hormonal contraceptives and increased risk Female Sexual Dysfunction.
‘. These important field of research important research topic for investigation, ‘said Dr. Irwin Goldstein, Editor-in-Chief of Journal of Sexual Medicine. ‘There are hundred of millions of women, especially young women at the beginning sexual living, the a regular basis hormonal contraceptives for many years. Irony is that such women a drug which provides the freedom to be provided from reproductive worry but the same women is no info that there are significant adverse sexual effects of, which may arise provided. .